Navigation Links
Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial
Date:10/11/2007

REDWOOD CITY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that, as part of a planned interim analysis, it would stop enrollment in a Phase 2 clinical trial evaluating the efficacy and safety of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The clinical trial utilized a two stage design to ensure there would be an adequate response rate to justify complete enrollment. Tumor response was evaluated at baseline and every six weeks using the Response Evaluation Criteria In Solid Tumors (RECIST). The first stage enrolled 21 patients as planned, but only one confirmed partial response was observed. If three or more responses were observed, an additional 29 patients would have been enrolled. Patients currently enrolled in the clinical trial will be given the option to continue in the trial.

"We are disappointed in the study results. While we recognize that response is not a perfect surrogate for survival, the low response rate indicates that glufosfamide is not sufficiently effective as a single agent for patients with small cell lung cancer. We had hoped to develop a better treatment option for patients with this disease, for whom the quality of life and treatment outcomes need improvement," said Barry Selick, Ph.D., chief executive officer of Threshold. "We want to thank the investigators, patients and their families for their participation in the study."

Phase 2 Clinical Trial Design

Approximately 50 patients with extensive recurrent sensitive small cell lung cancer, who had progressed at least 60 days after completing chemotherapy, were planned to enroll in the Phase 2, open-label, clinical trial at various s
'/>"/>

SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ... Closures - Global Strategic Business Report" report to their ... the US, Canada , Japan ... , Latin America , and Rest ... for Surgical Incision Closures in US$ Million by the following ...
(Date:6/2/2015)... BOSTON , June 2, 2015 ... an additional $75 million from its recently announced synthetic ... raised to $300 million. Investors have purchased Convertible Limited ... quarterly payments equal to 2.0% of any future global ... or are fully paid. Investors also have the option, ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Surgical Incision Closures - Global Strategic Business Report 2015 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
(Date:6/3/2015)... Veatch Consulting Services is excited to announce their achievement ... in April 2006, they have made it a priority ... and every year they have worked diligently in surpassing ... that they are off to a great start already ... year is the Customer Review site veatchconsultingreviews.weebly.com. At this ...
(Date:6/2/2015)... BALTIMORE, Md. – Ellarea Maria Cole Stansbury ... after being diagnosed with lupus. In spite of genetic ... which enhance health, lupus and other autoimmune related diseases ... Wellness ,” she offers a holistic approach to live ... an overview of some autoimmune diseases—especially lupus —including ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Concorde Career ... as President and COO. Bell will manage day-to-day operations ... “I’m looking forward to the opportunity to help our ... Bell said. “I joined Concorde in part due to ... that highlighted Concorde colleges in Memphis and Portland.” , ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 April 8th, ... music venue into Durkin Entertainment’s “RockNRolla Movie Awards” EcoLuxe ... Bend, that gathered some of the world’s top providers ... The event was organized by Debbie Durkin, Los Angeles’ ... film, the EcoLuxe Lounge is a premier red carpet ...
(Date:6/2/2015)... Residents looking for a new dentist ... more convenient location now that Coast Dental Kissimmee is ... E. Irlo Bronson Memorial Highway, Suite C-106, Kissimmee, FL ... mile away from its original location, and features a ... areas with digital intraoral and panoramic x-ray system and ...
Breaking Medicine News(10 mins):Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Concorde Career Colleges Announces New President and COO 2Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:Coast Dental Office Opening In Kissimmee with Expanded Technology 2
... in the March 2006 issue of Archives of Ophthalmology says ... risk of relapse of a vision-threatening eyelid condition called trichiasis.// ... clinical trial funded by the National Eye Institute (NEI), part ... ,It was found that azithromycin was better than the local ...
... Medicine in St. Louis say that a noninvasive approach ... developing drugs for cystic fibrosis and pneumonia. // Positron ... induced inflammation in the lungs of healthy volunteers. ... a new drug decreased lung inflammation, the options for ...
... you can’t wait for a appointment a local clinic now ... clear results in 10 minutes//, ,Chlamydia is the most ... no symptoms, and can be passed on to others without ... including problems in pregnancy and infertility in both men and ...
... long term will make the brain to lose its ability, gradually ... led by Lambros Messinis at the University Hospital of Patras in ... taken marijuana heavily. They smoked at least four joints a week ... New Scientist. ,Their brains were rustier than those ...
... is found to improve their kidney function in patients with heart ... he said that those patients who took 80 mg of the ... ,The drug is the world's top-selling prescription drug. The data of ... scientific meeting in Atlanta. ,50% of the patients, who ...
... Jordan said that the kingdom was untouched by the avian flu ... the joint effort of both the public and the government. He ... in the country. , The minister made the ... , In that occasion to celebrate this great achievement the ...
Cached Medicine News:Health News:Home Chlamydia Test 2
... Left Ventricular Assist System (LVAS) is a ... restore hemodynamic function and improve patient outcomes ... action of a single-moving part, the HeartMate ... support by pumping blood from the heart ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
... Bariatric Stand-On Scale is designed to accommodate ... physicians scales only weigh up to 300 ... surface, or patients position on the scale., ... profile only 1 1/4 inches high. ...
... hormone (PTH) is synthesized by the ... response to decreased extracellular calcium concentrations. ... resorption and decreasing calcium excretion by ... circulation, intact PTH is rapidly degraded ...
Medicine Products: